IL-12: immunological staging of multiple sclerosis and measure of response to therapy

To date, no ideal biological disease marker has been identified in multiple sclerosis (MS). As interleukin-12 (IL-12) is a key cytokine in the immunopathology of MS as well as of several other T-helper type 1 (Th1) mediated human autoimmune diseases, it has the potential of being a useful marker for disease activity.